| 30/07/26 | 15:30:00 | 30 Jul 2026 | | Director/PDMR Shareholding |
| 28/07/26 | 12:05:01 | 28 Jul 2026 | | New GSK flagship R&D centre in Cambridge |
| 28/07/26 | 12:00:00 | 28 Jul 2026 | | 2nd Quarter Results |
| 28/07/26 | 11:06:50 | 28 Jul 2026 | | Hansoh positive 2nd Phase III results for Riz-Rez |
| 24/07/26 | 15:30:00 | 24 Jul 2026 | | Director/PDMR Shareholding |
| 24/07/26 | 15:00:00 | 24 Jul 2026 | | Admission to Trading |
| 22/07/26 | 17:22:55 | 22 Jul 2026 | | Jideytro approved in US for certain lung cancers |
| 20/07/26 | 07:00:07 | 20 Jul 2026 | | Bexsero 1-dose booster EMA file acceptance |
| 17/07/26 | 12:00:01 | 17 Jul 2026 | | Audit tender conclusion |
| 17/07/26 | 09:30:00 | 17 Jul 2026 | | Camlipixant phase III results update |
| 16/07/26 | 15:30:00 | 16 Jul 2026 | | Director/PDMR Shareholding |
| 15/07/26 | 13:38:08 | 15 Jul 2026 | | GSK completes acquisition of Nuvalent, Inc |
| 14/07/26 | 15:30:01 | 14 Jul 2026 | | Director/PDMR Shareholding |
| 13/07/26 | 15:30:00 | 13 Jul 2026 | | Director/PDMR Shareholding |
| 13/07/26 | 07:00:10 | 13 Jul 2026 | | Positive Jemperli data in dMMR/MSI-H rectal cancer |
| 10/07/26 | 11:58:58 | 10 Jul 2026 | | Hansoh positive Phase III results for Riz-Rez |
| 09/07/26 | 15:30:00 | 9 Jul 2026 | | Director/PDMR Shareholding |
| 09/07/26 | 10:00:00 | 9 Jul 2026 | | Directorate change |
| 01/07/26 | 15:00:01 | 1 Jul 2026 | | Total Voting Rights |
| 29/06/26 | 15:00:00 | 29 Jun 2026 | | Holding(s) in Company |
| 29/06/26 | 15:00:00 | 29 Jun 2026 | | Transaction in Own Shares |
| 26/06/26 | 15:00:01 | 26 Jun 2026 | | Holding(s) in Company |
| 24/06/26 | 15:30:01 | 24 Jun 2026 | | Director/PDMR Shareholding |
| 24/06/26 | 14:52:05 | 24 Jun 2026 | | GSK announces tender offer to acquire Nuvalent |
| 23/06/26 | 15:30:01 | 23 Jun 2026 | | Director/PDMR Shareholding |
| 22/06/26 | 15:00:01 | 22 Jun 2026 | | Transaction in Own Shares |
| 17/06/26 | 16:06:03 | 17 Jun 2026 | | cUTI oral antibiotic Tebipenem approved by US FDA |
| 15/06/26 | 15:00:00 | 15 Jun 2026 | | Transaction in Own Shares |
| 12/06/26 | 07:00:06 | 12 Jun 2026 | | Momelotinib orphan drug designations for VEXAS |
| 11/06/26 | 15:30:01 | 11 Jun 2026 | | Director/PDMR Shareholding |
| 10/06/26 | 15:30:00 | 10 Jun 2026 | | Director/PDMR Shareholding |
| 09/06/26 | 17:51:15 | 9 Jun 2026 | | Dr Hal Barron – New Directorship |
| 09/06/26 | 07:00:01 | 9 Jun 2026 | | GSK enters agreement to acquire Nuvalent, Inc. |
| 08/06/26 | 15:00:00 | 8 Jun 2026 | | Transaction in Own Shares |
| 01/06/26 | 15:00:00 | 1 Jun 2026 | | Total Voting Rights |
| 01/06/26 | 15:00:00 | 1 Jun 2026 | | Transaction in Own Shares |
| 28/05/26 | 09:30:00 | 28 May 2026 | | Positive Phase 3 data for bepirovirsen |
| 27/05/26 | 15:30:00 | 27 May 2026 | | Director/PDMR Shareholding |
| 26/05/26 | 15:00:00 | 26 May 2026 | | Admission to Trading |
| 26/05/26 | 15:00:00 | 26 May 2026 | | Transaction in Own Shares |
| 22/05/26 | 10:30:28 | 22 May 2026 | | Q2 2026 Results Date Confirmed - 28 July 2026 |
| 20/05/26 | 15:30:01 | 20 May 2026 | | Director/PDMR Shareholding |
| 19/05/26 | 15:30:01 | 19 May 2026 | | Director/PDMR Shareholding |
| 18/05/26 | 15:00:00 | 18 May 2026 | | Transaction in Own Shares |
| 18/05/26 | 07:00:09 | 18 May 2026 | | Japan MHLW approves Arexvy for adults 18-49 AIR |
| 14/05/26 | 15:30:00 | 14 May 2026 | | Director/PDMR Shareholding |
| 11/05/26 | 15:30:00 | 11 May 2026 | | Director/PDMR Shareholding |
| 11/05/26 | 07:05:00 | 11 May 2026 | | Collaboration with CTTQ for bepirovirsen |
| 11/05/26 | 07:00:10 | 11 May 2026 | | GSK - final tranche of share buyback programme |
| 06/05/26 | 18:22:16 | 6 May 2026 | | Result of AGM |
